Financings in Brief: Atrix
This article was originally published in The Gray Sheet
Atrix: Proposes to merge with Vipont Royalty Income Fund, Ltd. in a stock-swap transaction valued at $3.5 mil. Under terms of the deal, Fort Collins, Colorado-based development stage firm Atrix would exchange less than 9% of its 7.9 mil. outstanding shares for Vipont. Vipont, a funding vehicle formed in 1987, is jointly developing with Atrix the Atrigel injectable gel drug delivery system for use with the drug doxycycline to treat periodontal disease; Phase III trials are ongoing, a new drug application submission to FDA is anticipated in the first quarter of 1997. Atrix' second product, Atrisorb, is a guided tissue regeneration barrier for use in conjunction with gum surgery to promote tissue regeneration and treat periodontitis; a 510(k) submission is anticipated by year end. Vipont will approve or disapprove the plan Sept. 27...
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.